1月16日，国发股份发布2025年度业绩预告称，预计全年实现营业收入约3.3亿元，扣除无关收入后仍为 3.3亿元；预计归母净亏损约8500万元，同比减亏900万元，减亏幅度10%；扣非归母净亏损约8550万 元，同比减亏450万元。业绩预亏主要受子公司高盛生物盈利转亏、制药板块营收下滑及商誉减值计提 影响。 2月24日，国发股份（600538.SH）发布公告，针对上海证券交易所关于公司2025年度业绩预告的问询 函作出详细回复，就营业收入合规性、医药流通增速合理性及商誉减值等核心问题逐一说明。公司明确 营收扣除符合监管规定，医药流通增长具备业务支撑，同时披露拟对全资子公司广州高盛生物计提约 6200万元商誉减值。 上交所对公司医药流通业务增速高于行业水平提出质疑，要求详细说明增长合理性。国发股份从业务结 构、物流模式、区域市场、季度分布四方面进行了回应。 国发股份表示，公司医药流通收入以医院销售为主，占比达86%，快批、零售等板块有所下滑；物流以 自有仓库与配送体系为主，仅单一医院医疗器械合作使用第三方仓储，收入确认政策未发生变更，以客 户签收或实际使用为依据。 从区域来看，公司核心市场北部湾三市药品市场增速 ...

2月23日，国发股份（600538）（600538）发布公告，就上海证券交易所此前关于公司2025年度业绩预告的问询函进行了详细回复。公告披露并回答了有 关公司2025年度业绩预告相关财务问题，主要分为营业收入构成、主要业务板块经营情况、客户结构以及拟计提商誉减值准备等三个部分。 此前，1月16日，国发股份发布公告，公司预计2025年度实现营业收入约3.3亿元，归母净亏损约8500万元；扣非归母净亏损8550万元左右。与2024年度相 比，公司归母净利润亏损减少900万元，同比减少亏损10%；扣非归母净亏损减少450万元左右。 业绩预亏的主要原因包括全资子公司广州高盛生物科技有限公司因市场竞争加剧，营业收入同比下降约10%，毛利率下降约3%，导致其净利润由盈利转 为亏损。 此外，制药厂因生产线维护和市场产品调整，营业收入较上年同期下降约30%，亏损同比增加。同时，公司预计计提商誉减值金额约6200万元。 公司业绩预告显示，预计2025年度实现营业收入约3.3亿元，扣除与主营业务无关的业务收入和不具备商业实质的营业收入仍为3.3亿元；归属于母公司所 有者的净利润-0.85亿元。 上交所要求公司补充说明营业收入扣 ...

南方财经2月24日电，国发股份(600538.SH)2026年2月24日公告，回复了上海证券交易所关于其2025年 度业绩预告事项的问询函。交易所主要关注三大问题：业绩构成与合规性、医药流通业务增长合理性， 以及大额商誉减值。关于业绩，问询函要求公司说明营业收入扣除情况。公司回复称，2025年预计营收 约3.3亿元，扣除与主营业务无关的收入248.08万元后，营收为3.27亿元。分业务看，医药流通业务收入 占比近58%，同比增长4.43%；而司法IVD与医药制造业务收入分别下降10%和23.44%。公司前五大客 户在医药流通板块稳定，在司法IVD板块因招投标竞争加剧变动较大，并称不存在收入确认政策变更或 通过新客户实现异常交易的情形。对于医药流通业务收入增长，交易所问询其是否与行业趋势匹配。公 司解释，增长主要源于医院销售，特别是集采品种和麻精药品的销售增加。业务交货以送货上门或快递 为主，以客户签收作为收入确认时点。公司认为其4.43%的增长率，与北部湾区域医药市场约4%-4.5% 的增速及同行业公司表现相符。针对连续大额商誉减值，交易所要求说明减值是否充分。公司披露，其 收购的子公司高盛生物因公安客户预算 ...

Group 1 - The core viewpoint of the articles highlights the efforts of Weifang City's Market Supervision Administration in Shandong Province to enhance drug safety governance and regulatory efficiency through innovative monitoring models and risk management strategies [1][2]. Group 2 - A comprehensive risk prevention system has been established, including a collaborative risk consultation mechanism at provincial, municipal, and county levels, identifying 44 risk points in drug and medical device sectors, and implementing closed-loop management [1]. - The administration has conducted 8 expert evaluation meetings to identify 222 risk hazards and reported 35,000 adverse reaction monitoring reports, leading to the first proactive recall of a medical device by a multinational company in the province [1]. - A "clean source" action was initiated in drug distribution, resulting in 123 special case investigations and the development of eight measures to ensure quality and safety responsibilities among medical device businesses [1]. Group 3 - Collaborative efforts with health, medical insurance, public security, and education departments have led to comprehensive regulatory inspections of 170 drug and medical device units and special checks on 93 retail drug units [2]. - The administration has improved the vaccine information sharing mechanism and conducted two rounds of comprehensive inspections of vaccine usage units to ensure vaccine quality and safety [2]. Group 4 - Digital empowerment has been emphasized to enhance smart regulatory capabilities, transitioning from manual to technical defenses through the establishment of a digital regulatory archive [2]. - The Weifang City "Three Medicines" data sharing center has developed a smart regulatory system for practicing pharmacists, which is currently in trial operation to improve regulatory efficiency [2]. - The real-name registration system for narcotic and psychotropic drugs has been optimized, covering 11,000 drug operating units, enabling real-time monitoring and automatic data collection [2].

Core Viewpoint - The article emphasizes the importance of strengthening the supervision and management of narcotic drugs and precursor chemicals to prevent illegal use and ensure safe, legal usage in the healthcare sector [1] Group 1: Supervision and Management - The police conducted special inspections in hospitals, pharmacies, and enterprises to ensure compliance with regulations regarding narcotic drugs and precursor chemicals [1] - Inspections included reviewing inventory records and physical checks of narcotic drugs and precursor chemicals to verify legality and traceability [1] Group 2: Awareness and Responsibility - The initiative aimed to enhance the awareness of drug control, legal compliance, and safety among healthcare professionals and staff in the region [1] - The police urged responsible parties to implement better management systems and ensure lawful operations and proper usage of narcotic drugs [1]

Group 1: Financial Performance - In Q3 2025, the company achieved an operating revenue of 622.11 million yuan, representing a year-on-year growth of 4.22% [2] - The net profit attributable to shareholders reached 38.4 million yuan, with a year-on-year increase of 31.41% [2] - The net profit excluding non-recurring items grew by 36.83% [2] Group 2: Business Collaboration and Expansion - Following its integration into the General Technology Group, the company has accelerated business collaboration with medical institutions, successfully opening 138 accounts across 25 provinces by the end of September 2025 [2] - The company has enhanced its creditworthiness, leading to broader financing channels and a noticeable decrease in financing costs [2] Group 3: Pharmaceutical Operations - The company is one of three national wholesale enterprises for narcotic and psychotropic drugs, holding regional wholesale qualifications in 15 provinces, with a sales network covering 31 provinces and autonomous regions [3] - The company has a competitive advantage in narcotic drug distribution in regions such as Sichuan, Chongqing, Guizhou, Qinghai, and Tibet [3] Group 4: Retail Operations - By the end of September 2025, the company operated retail pharmacies across 22 provinces, municipalities, and autonomous regions, including 210 community health pharmacies and 832 DTP prescription pharmacies [3] - The company plans to strengthen its retail omnichannel construction and enhance its nationwide network layout, focusing on multi-dimensional marketing services and patient management systems [3]

Core Viewpoint - The Ordos Market Supervision Administration is implementing multiple measures to strengthen the supervision and management of narcotic and psychotropic drugs, ensuring public safety and health [1][2] Group 1: Regulatory Actions - The "Qingyuan 2025" special action plan has been developed to clarify the focus and division of tasks for the supervision of narcotic and psychotropic drugs [1] - There is an emphasis on enhancing supervision of special drug raw materials and outpatient treatment for drug addiction, preventing illegal circulation of these drugs [1] - Comprehensive inspections of drug operating and using units are being conducted, focusing on the qualifications, sales channels, storage conditions, and usage records of narcotic drugs [1] Group 2: Risk Management - A risk consultation meeting has been organized to identify risk points in the circulation and use of narcotic drugs, leading to the formulation of targeted control measures [1] - Ongoing monitoring and special rectification efforts are being strengthened, particularly in medical institutions regarding the management of narcotic drugs and monitoring of drug abuse [1] - As of now, 327 medical institutions have been inspected, with 825 law enforcement personnel deployed to address issues related to expired narcotic drugs [1] Group 3: Online and Offline Monitoring - There is a continuous effort to monitor and combat the illegal online sale of narcotic drugs, with both online inspections and third-party monitoring being conducted [2] - No illegal sales of narcotic drugs through the internet have been found in the Ordos area to date [2] - Future actions will include enhancing follow-up inspections of medical institutions, improving risk prevention mechanisms, and strengthening online regulatory measures [2]

Summary of Key Points from the Conference Call Industry Overview - The healthcare sector in China is experiencing increased government support, with national fiscal health expenditure reaching 1.2 trillion yuan in the first seven months of 2025, a year-on-year increase of 5.3% [1][3][4] - The pharmaceutical industry is showing signs of recovery, with the added value of the pharmaceutical manufacturing industry growing by 2.4% in July 2025, although this is below the national industrial average growth of 5.7% [1][5] Key Insights and Arguments - **Healthcare Expenditure**: The growth in healthcare expenditure indicates a strong government commitment to the sector, with a 13.9% increase compared to the same period in 2019 [1][4] - **Retail Market Pressure**: The retail market for Chinese and Western medicines is under pressure, with a growth rate of only 1.2%, significantly lower than the overall retail growth of 4.8% [1][6] - **Inpatient Treatment Decline**: There is a noticeable decline in inpatient treatment volumes, with various cities reporting decreases in hospitalization rates [1][7] - **Medical Device Exports**: Medical device exports have performed well, particularly for endoscopes and MRI equipment, with growth rates of 31.8% and 8.7% respectively [1][8] Additional Important Content - **Insurance Fund Trends**: The insurance fund's income has shown steady growth at 6.9% year-on-year, but expenditures have decreased by 1% in the same period, marking the first negative growth this year [2] - **CRO and BioTech Performance**: The BioTech and CRO sectors are performing relatively well, with some companies achieving over 40% growth due to domestic commercialization [11][12] - **Impact of Tariffs**: Tariffs imposed on medical devices have significantly affected exports, particularly for gloves, which saw an 18% decline [10] - **Capital Expenditure Trends**: The overall capital expenditure (CAPEX) of listed companies has been declining for three consecutive years, with the retail pharmacy sector experiencing the most significant drop [18] - **Risks in Innovation**: The innovative pharmaceutical sector faces risks from domestic procurement policies and geopolitical factors, which could impact industry dynamics [22] This summary encapsulates the critical insights and trends discussed in the conference call, highlighting the current state and future outlook of the healthcare and pharmaceutical industries in China.

Group 1: Financial Performance - The company's operating revenue for the first half of 2025 reached 41.188 billion yuan, representing a year-on-year growth of 3.54% [2] - The net profit attributable to shareholders was 2.82 billion yuan, with a year-on-year increase of 18.56% [2] - The net profit excluding non-recurring items was 2.77 billion yuan, showing a year-on-year growth of 26.68% [2] Group 2: Third-party Storage and Distribution Business - The revenue from the third-party storage and distribution business exceeded 15 million yuan during the reporting period, expanding into various fields including traditional Chinese medicine, e-commerce, medical devices, and radiopharmaceuticals [2] Group 3: Narcotic and Psychotropic Drugs - The sales of narcotic and psychotropic drugs amounted to 1.736 billion yuan, reflecting a year-on-year increase of 19.07% [3] - The company is one of three national wholesale enterprises for narcotic drugs, with a sales network covering all 31 provinces and regions [3] Group 4: Financial Cost Management - Financial costs decreased significantly, with a reduction of 165 million yuan, marking a year-on-year decline of 30.35% [3] - The financial cost rate reached a five-year low, with expectations for further reductions in the future [3] Group 5: Collaboration with General Technology Group - The company accelerated collaboration with medical institutions under the General Technology Group, opening 104 accounts in 22 provinces, including 89 grade hospitals [3] - A strategic cooperation agreement was signed with General Health and China Pharmaceutical to enhance resource integration and optimize supply chain management [3]

Group 1: Market Value Management - The company considers market value management a key task for the year, focusing on improving operational management and utilizing various methods such as information disclosure, cash dividends, and share buybacks to enhance market value [2][3] - A market value management system was established in June 2025, with a share buyback plan approved by the shareholders in July, allowing for a buyback of between 80 million to 100 million yuan [3] - On August 14, 2025, the company executed its first share buyback, acquiring 3,762,300 shares for a total payment of 19,999,259.00 yuan (excluding transaction fees) [3] Group 2: Business Expansion and Projects - As of mid-2025, the company has launched 199 SPD projects across 23 provinces in China, with plans to initiate new projects as needed [3] - The company currently operates 205 DTP pharmacies, including 192 direct-operated and 13 franchised, with plans to further develop this business segment [4] Group 3: Competitive Strategy - The company aims to build a differentiated competitive system focusing on "strengthening barriers, enhancing value, and exploring growth," leveraging its state-owned enterprise background for synergy in the pharmaceutical commercial sector [4] - Strategies include enhancing logistics through smart delivery methods and expanding into high-growth niche markets such as medical devices and DTP pharmacies [4] Group 4: Research and Development - The company's R&D primarily focuses on generic drugs, adhering to international standards, with four products already approved and three in commercial production [4]